<i>Mycobacterium tuberculosis</i> Decaprenylphosphoryl-β-<scp>d</scp>-ribose Oxidase Inhibitors: Expeditious Reconstruction of Suboptimal Hits into a Series with Potent in Vivo Activity
作者:Jennifer A. Borthwick、Carlos Alemparte、Ian Wall、Benjamin C. Whitehurst、Argyrides Argyrou、Glenn Burley、Paco de Dios-Anton、Laura Guijarro、Maria Candida Monteiro、Fatima Ortega、Colin J Suckling、Julia Castro Pichel、Monica Cacho、Robert J. Young
DOI:10.1021/acs.jmedchem.9b01561
日期:2020.3.12
Mycobacterium tuberculosis and has recently been studied as a potential drug target, with inhibitors progressing to clinical studies. Here we describe the identification of a novel series of morpholino-pyrimidine DprE1 inhibitors. These were derived from a phenotypic high-throughput screening (HTS) hit with suboptimal physicochemical properties. Optimization strategies included scaffold-hopping, synthesis, and
癸烯基磷酸基-β-d-核糖2'-表异构酶(DprE1)是结核分枝杆菌中必不可少的酶,最近已被研究为潜在的药物靶标,抑制剂已进入临床研究。在这里,我们描述了一系列新的吗啉代嘧啶DprE1抑制剂的鉴定。这些来自具有最佳物理化学性质的表型高通量筛选(HTS)。优化策略包括脚手架跳跃,合成和先导化合物片段的评估以及以性能为中心的优化。所得的优化化合物具有大大改善的理化性质,并保持了酶和细胞效能。这些分子在体内结核鼠感染模型中显示出有效的功效。